TCP11L2

Summary

TCP11L2 (t-complex 11 like 2, HGNC:28627) is a protein-coding gene on chromosome 12q23.3, encoding T-complex protein 11-like protein 2 (Q8N4U5). Promotes the migration of muscle-derived satellite cells (MDSCs) during differentiation throught interaction with FMNL2 and therefore may participate in microfilament assembly.

Predicted to be involved in muscle cell migration and signal transduction. Predicted to be located in cytoskeleton. Predicted to be part of cytoplasm.

Source: NCBI Gene 255394 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_152772

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28627
Approved symbol	TCP11L2
Name	t-complex 11 like 2
Location	12q23.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC40368
Ensembl gene	ENSG00000166046
Ensembl biotype	protein_coding
OMIM	619889
Entrez	255394

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 11 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000299045, ENST00000546625, ENST00000547153, ENST00000548428, ENST00000549906, ENST00000551228, ENST00000551802, ENST00000552690, ENST00000553098, ENST00000553143, ENST00000718461, ENST00000910255, ENST00000910256

RefSeq mRNA: 2 — MANE Select: NM_152772 NM_001286262, NM_152772

CCDS: CCDS66456, CCDS9104

Canonical transcript exons

ENST00000299045 — 10 exons

Exon	Start	End
ENSE00001099287	106321486	106321706
ENSE00001099317	106336032	106336213
ENSE00001099320	106335639	106335826
ENSE00001099330	106340826	106340998
ENSE00001165377	106318344	106318464
ENSE00001213960	106346286	106347003
ENSE00001213986	106311041	106311232
ENSE00003572690	106323510	106323646
ENSE00003791404	106314358	106314493
ENSE00003849719	106302733	106302941

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 95.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.3599 / max 212.3928, expressed in 1561 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
127819	4.6516	1167
127818	1.7563	1074
127817	0.5687	115
127820	0.3917	143
127813	0.2375	49
127812	0.2314	51
127821	0.1923	72
127815	0.1152	34
206878	0.0902	36
127814	0.0694	26

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow cell	CL:0002092	95.14	gold quality
right uterine tube	UBERON:0001302	93.31	gold quality
calcaneal tendon	UBERON:0003701	92.26	gold quality
blood	UBERON:0000178	91.49	gold quality
tendon	UBERON:0000043	91.01	gold quality
corpus callosum	UBERON:0002336	90.95	gold quality
lower esophagus mucosa	UBERON:0035834	90.48	gold quality
tendon of biceps brachii	UBERON:0008188	90.26	gold quality
monocyte	CL:0000576	88.87	gold quality
leukocyte	CL:0000738	88.86	gold quality
adrenal tissue	UBERON:0018303	88.73	gold quality
buccal mucosa cell	CL:0002336	88.70	gold quality
apex of heart	UBERON:0002098	87.83	gold quality
medial globus pallidus	UBERON:0002477	87.51	gold quality
colonic epithelium	UBERON:0000397	87.42	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.23	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	87.20	gold quality
muscle of leg	UBERON:0001383	85.93	gold quality
gastrocnemius	UBERON:0001388	85.57	gold quality
oocyte	CL:0000023	84.88	gold quality
granulocyte	CL:0000094	84.86	gold quality
globus pallidus	UBERON:0001875	84.85	gold quality
heart left ventricle	UBERON:0002084	84.83	gold quality
minor salivary gland	UBERON:0001830	84.50	gold quality
sural nerve	UBERON:0015488	84.29	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.14	gold quality
esophagus mucosa	UBERON:0002469	84.14	gold quality
cardiac ventricle	UBERON:0002082	84.00	gold quality
stromal cell of endometrium	CL:0002255	83.91	gold quality
islet of Langerhans	UBERON:0000006	83.82	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

50 targeting TCP11L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-6740-3P	99.48	68.49	1392

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tcp11l2	ENSDARG00000027316
mus_musculus	Tcp11l2	ENSMUSG00000020034
rattus_norvegicus	Tcp11l2	ENSRNOG00000007587
drosophila_melanogaster	CG16721	FBGN0029820
caenorhabditis_elegans		WBGENE00010875

Paralogs (4): TCP11 (ENSG00000124678), TCP11L1 (ENSG00000176148), TCP11X2 (ENSG00000215029), TCP11X1 (ENSG00000268235)

Protein

Protein identifiers

T-complex protein 11-like protein 2 — Q8N4U5 (reviewed: Q8N4U5)

All UniProt accessions (7): Q8N4U5, F8VRQ3, F8VU20, F8VW27, F8W0R5, F8W1M6, G3V1Z2

UniProt curated annotations — full annotation on UniProt →

Function. Promotes the migration of muscle-derived satellite cells (MDSCs) during differentiation throught interaction with FMNL2 and therefore may participate in microfilament assembly.

Subunit / interactions. Interacts with FMNL2; this interaction promotes muscle-derived satellite cell (MDSC) migration and differentiation.

Subcellular location. Cytoplasm. Cytoskeleton.

Similarity. Belongs to the TCP11 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N4U5-1	1	yes
Q8N4U5-2	2

RefSeq proteins (2): NP_001273191, NP_689985* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008862	Tcp11	Family

Pfam: PF05794

UniProt features (11 total): sequence variant 3, sequence conflict 2, splice variant 2, chain 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N4U5-F1	81.44	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 16

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 182 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE45365_NK_CELL_VS_CD8_TCELL_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, FREAC3_01, GATA6_01, WTGAAAT_UNKNOWN, HFH4_01, RYTTCCTG_ETS2_B, CUI_TCF21_TARGETS_2_DN, CART1_01, GOBP_MUSCLE_CELL_MIGRATION, EVI1_04, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE

GO Biological Process (2): signal transduction (GO:0007165), muscle cell migration (GO:0014812)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cell migration	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

487 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TCP11L2	TMEM263	Q8WUH6	558
TCP11L2	POLR3B	Q9NW08	536
TCP11L2	GPR137C	Q8N3F9	472
TCP11L2	TMEM234	Q8WY98	462
TCP11L2	GRPR	P30550	442
TCP11L2	MGAT4C	Q9UBM8	433
TCP11L2	XKRX	Q6PP77	430
TCP11L2	PRDM4	Q9UKN5	428
TCP11L2	PTPRK	Q15262	402
TCP11L2	ZSCAN20	P17040	397
TCP11L2	ZNF286A	Q9HBT8	391
TCP11L2	DIPK1C	Q0P6D2	390
TCP11L2	ARHGAP23	Q9P227	387
TCP11L2	ENKUR	Q8TC29	384
TCP11L2	DYNLT2	Q8IZS6	380

IntAct

50 interactions, top by confidence:

A	B	Type	Score
TUBA4A	TCP11L2	psi-mi:“MI:0915”(physical association)	0.800
TUBA1C	TXNDC9	psi-mi:“MI:0914”(association)	0.730
TUBA1B	TXNDC9	psi-mi:“MI:0914”(association)	0.640
TUBA1C	CCT6A	psi-mi:“MI:0914”(association)	0.640
TUBA4A	TXNDC9	psi-mi:“MI:0914”(association)	0.640
TUBA1A	TUBA4A	psi-mi:“MI:0914”(association)	0.610
TCP11L2	ACTA2	psi-mi:“MI:0915”(physical association)	0.560
HGS	TCP11L2	psi-mi:“MI:0915”(physical association)	0.560
TCP11L2	CXXC1	psi-mi:“MI:0915”(physical association)	0.560
TCP11L2	TUBA8	psi-mi:“MI:0915”(physical association)	0.560
BAG6	TCP11L2	psi-mi:“MI:0915”(physical association)	0.560
KLF11	TCP11L2	psi-mi:“MI:0915”(physical association)	0.560
TUBA3E	TCP11L2	psi-mi:“MI:0915”(physical association)	0.560
TTC5	TUBA4A	psi-mi:“MI:0914”(association)	0.530
TUBA1C	TUBA4A	psi-mi:“MI:0914”(association)	0.530
TUBA4A	PLD2	psi-mi:“MI:0914”(association)	0.530
TUBA1A	TUBAL3	psi-mi:“MI:0914”(association)	0.420
ACAD11	TCP11L2	psi-mi:“MI:0915”(physical association)	0.400
TUBA1A	CAPZB	psi-mi:“MI:0914”(association)	0.350
TUBA1A	KIF2A	psi-mi:“MI:0914”(association)	0.350
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350
	TXNDC9	psi-mi:“MI:0914”(association)	0.350

BioGRID (34): TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Proximity Label-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), TCP11L2 (Proximity Label-MS), TCP11L2 (Affinity Capture-MS), TCP11L2 (Affinity Capture-RNA)

ESM2 similar proteins: A0JMW6, A1A535, A1A5P5, A1L1L2, A1L2I9, A2BID5, A4FV45, A7Z033, F1QN74, P56695, Q08CY4, Q0KK59, Q14D04, Q2PW47, Q3UHQ6, Q568Z0, Q5FWU8, Q5JWR5, Q5PQS3, Q5SPP5, Q5U249, Q642P2, Q68F70, Q68Y81, Q6DRL5, Q6GPP1, Q6GQ26, Q6IV68, Q6NUQ4, Q6PI53, Q7SYB2, Q7Z3E5, Q7ZYV9, Q80V62, Q80X82, Q8BL99, Q8BM55, Q8CIM8, Q8JGR7, Q8K1H7

Diamond homologs: A7Z033, B4DZS4, Q01755, Q568Z0, Q5H9J9, Q5XI00, Q8BTG3, Q8K1H7, Q8N4U5, Q8WWU5, Q9NUJ3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 31 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane	9	195.8×	2e-18
Transport of connexons to the plasma membrane	9	195.8×	2e-18
Formation of tubulin folding intermediates by CCT/TriC	11	186.1×	7e-22
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	11	179.5×	7e-22
Gap junction trafficking and regulation	9	171.3×	5e-18
Gap junction trafficking	9	171.3×	5e-18
Post-chaperonin tubulin folding pathway	9	171.3×	5e-18
Activation of AMPK downstream of NMDARs	9	137.0×	5e-17

GO biological processes:

GO term	Partners	Fold	FDR
mitotic cell cycle	10	44.6×	1e-12
microtubule cytoskeleton organization	11	44.5×	8e-14
cell division	6	9.2×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1426 predictions. Top by Δscore:

Variant	Effect	Δscore
12:106311233:G:GG	donor_gain	1.0000
12:106314354:TCAG:T	acceptor_loss	1.0000
12:106314355:CA:C	acceptor_loss	1.0000
12:106314356:A:AG	acceptor_gain	1.0000
12:106314356:A:T	acceptor_loss	1.0000
12:106314357:G:GT	acceptor_gain	1.0000
12:106314357:GC:G	acceptor_gain	1.0000
12:106314357:GCA:G	acceptor_gain	1.0000
12:106314357:GCAA:G	acceptor_gain	1.0000
12:106314357:GCAAC:G	acceptor_gain	1.0000
12:106314491:G:GT	donor_gain	1.0000
12:106314491:GAG:G	donor_gain	1.0000
12:106314493:GGT:G	donor_loss	1.0000
12:106314495:T:A	donor_loss	1.0000
12:106318342:A:AG	acceptor_gain	1.0000
12:106318342:AGTTT:A	acceptor_gain	1.0000
12:106318343:G:GA	acceptor_gain	1.0000
12:106318343:GTTT:G	acceptor_gain	1.0000
12:106318343:GTTTG:G	acceptor_gain	1.0000
12:106321480:CTGTA:C	acceptor_loss	1.0000
12:106321481:TGTA:T	acceptor_loss	1.0000
12:106321482:GTAGA:G	acceptor_loss	1.0000
12:106321483:TAGA:T	acceptor_loss	1.0000
12:106321484:A:AG	acceptor_gain	1.0000
12:106321485:G:GT	acceptor_gain	1.0000
12:106321485:GA:G	acceptor_gain	1.0000
12:106321485:GAT:G	acceptor_gain	1.0000
12:106321485:GATT:G	acceptor_gain	1.0000
12:106321485:GATTC:G	acceptor_gain	1.0000
12:106321509:C:CA	acceptor_gain	1.0000

AlphaMissense

3440 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:106335662:T:A	W266R	0.994
12:106335662:T:C	W266R	0.994
12:106318381:T:C	F111L	0.987
12:106318383:C:A	F111L	0.987
12:106318383:C:G	F111L	0.987
12:106321547:T:C	L159S	0.986
12:106323619:T:C	F249L	0.986
12:106323621:C:A	F249L	0.986
12:106323621:C:G	F249L	0.986
12:106321559:T:C	L163P	0.983
12:106323620:T:C	F249S	0.983
12:106321573:G:C	A168P	0.982
12:106321652:G:C	R194P	0.982
12:106335664:G:C	W266C	0.982
12:106335664:G:T	W266C	0.982
12:106321641:T:G	C190W	0.981
12:106318386:G:C	W112C	0.979
12:106318386:G:T	W112C	0.979
12:106321490:T:C	L140P	0.979
12:106335776:A:C	S304R	0.979
12:106335778:T:A	S304R	0.979
12:106335778:T:G	S304R	0.979
12:106336036:T:C	L322P	0.979
12:106318384:T:A	W112R	0.978
12:106318384:T:C	W112R	0.978
12:106321571:A:C	Q167P	0.977
12:106321616:T:A	V182D	0.977
12:106335768:T:C	L301P	0.973
12:106346450:T:C	F494L	0.973
12:106346452:T:A	F494L	0.973

dbSNP variants (sampled 300 via entrez): RS1000005201 (12:106327459 C>T), RS1000005315 (12:106299690 G>C), RS1000057886 (12:106300016 C>A,T), RS1000105350 (12:106335662 T>C), RS1000195425 (12:106323329 A>G), RS1000285752 (12:106328949 C>T), RS1000297254 (12:106317157 C>G,T), RS1000355264 (12:106299234 A>T), RS1000441459 (12:106327763 A>G), RS1000507574 (12:106311335 C>T), RS1000559762 (12:106304431 A>G), RS1000594350 (12:106310994 G>A,C,T), RS1000636137 (12:106329250 A>G), RS1000759760 (12:106340405 T>C), RS1000829382 (12:106316853 A>G)

Disease associations

OMIM: gene MIM:619889 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001635_2	Tourette syndrome	6.000000e-06
GCST010002_222	Refractive error	1.000000e-12
GCST010703_94	Brain morphology (MOSTest)	6.000000e-52

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects cotreatment	2
sodium arsenite	decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Nickel	decreases expression	2
Oxygen	decreases reaction, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	increases expression, decreases reaction	1
GSK-J4	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
beauvericin	affects cotreatment, decreases expression	1
alpha phellandrene	increases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
nickel chloride	increases expression	1
lei gong teng	increases expression	1
epigallocatechin gallate	increases expression	1
pentanal	decreases expression	1
phenethyl isothiocyanate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
enniatins	affects cotreatment, decreases expression	1
nutlin 3	increases expression	1
jinfukang	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
(+)-JQ1 compound	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety